Ireland is missing about 73 clinical trials a year compared with ten similar European countries, and it comes last of the 11 for trials of medicines, a Priya Life Science analysis of public registry data shows. Ireland starts 11.8 trials of medicines a year for every million people. The median of the ten comparison countries is 18.1.
The figures come from Living Proof No. 1, a data story published on 15 November 2026 at priyalifescience.com/trials-index/proof. It is built on the Ireland Clinical Trials Performance Index, which compares Ireland with Austria, Belgium, Czechia, Denmark, Finland, the Netherlands, Norway, Portugal, Sweden and Switzerland using ClinicalTrials.gov records and Eurostat population figures. Every computed number in the story can be recalculated by the reader in their own browser, from the same trial-level file we used.
- The gap: from 2021 to 2025, trials with at least one Irish site started at 21.3 a year per million people, against a comparison median of 34.7. Ireland ranks 10th of 11, ahead only of Portugal.
- In trials: that is about 116 trials a year. Reaching the median would take about 73 more.
- Medicines: for trials of medicines (phase 1 to 4), Ireland is last of 11, at 11.8 per million against 18.1.
- Not a bad year: Ireland was below the comparison median in every year counted since 2014.
- Strength: once open, Irish trials are usually finished and reported. Ireland ranks 4th for trials completed rather than stopped early and 3rd for posting results.
- Right of reply: the Department of Health, the Health Research Board and the HRB National Clinical Trials Office were sent the findings on 5 November 2026. None had replied by publication.
How far behind is Ireland?
From 2021 to 2025, 579 interventional trials started with at least one site in Ireland, an average of about 116 a year. Divided by the population on 1 January 2025, that is 21.3 trials a year for every million people. The ten comparison countries have a median of 34.7. Bringing Ireland level with that median would mean about 73 more trials a year.
Denmark, which has a similar population, leads the group at 82.6 trials per million a year, 3.9 times Ireland's rate. Portugal is the only country below Ireland, at 19.3.
| Country | Trials per million a year (total trials) |
|---|---|
| Denmark | 82.6 (2,476) |
| Belgium | 50.9 (3,026) |
| Switzerland | 41.3 (1,867) |
| Norway | 36.2 (1,012) |
| Netherlands | 34.8 (3,138) |
| Sweden | 34.5 (1,827) |
| Czechia | 29.1 (1,587) |
| Austria | 27.5 (1,263) |
| Finland | 24.7 (696) |
| Ireland | 21.3 (579) |
| Portugal | 19.3 (1,101) |
Which trials are missing?
The registry lets the gap be split two ways: by what is being tested, and by who sponsors the trial.
Trials of medicines, which carry a phase 1 to 4 label, start in Ireland at 11.8 a year per million people, against a median of 18.1. No other country in the group starts fewer. The margin at the bottom is small: three more Irish trials of medicines over the five years would have lifted Ireland above Portugal. Reaching the median would take about 34 more trials of medicines a year. Other studies, of devices, surgery, exercise, diet or how care is organised, start at 9.5 per million against 16.8.
By sponsor, industry-sponsored trials start at 12.5 per million a year against a median of 15.9, about four-fifths of the usual level. Counting only company-sponsored trials of medicines, Ireland is again 11th of 11. Trials not sponsored by industry, run by hospitals, universities and research groups in Ireland or abroad, start at 8.8 per million against 19.1, less than half.
Of the 73 missing trials a year, industry accounts for 18. The other 55 are not sponsored by industry. That figure is a difference, not a separate count, and it is less certain than the medicines figure: about three in four non-industry studies, in both Ireland and Denmark, are not trials of medicines, and countries differ in how routinely they register such studies.
Has Ireland always been below the median?
Yes, in every year counted. Ireland was below the comparison median in all 12 years from 2014 to 2025. In 2025 it started 21.9 trials per million against a median of 29.3. The story's own reading is that the gap narrowed in 2025 more because the comparison median fell than because Ireland rose, and 2025 counts may still grow as late registrations arrive.
The story also tests whether the finding survives other ways of counting. It holds for industry-sponsored trials only, for non-industry trials only, without Denmark, against only the countries closest to Ireland in size, and for medicines and non-medicines separately. It does not hold against Portugal alone, and the story says so.
Why is Ireland behind?
The registry shows the gap but not its cause. In August 2024 the then Minister for Health, Stephen Donnelly, set up a National Clinical Trials Oversight Group, saying: "I want to double the number of clinical trials taking place in Ireland." The group reported in November 2025. It named obstacles including contract negotiation, costing processes and data-protection compliance, shortages of key skills and a reliance on short-term contracts, and the lack of a national electronic health record. It made 20 recommendations, including a clinical trials advisory council by early 2026 and a national clinical trials body by the third quarter of 2027. In July 2026 Prof Donal Brennan, who chaired the oversight group, was appointed to lead the new council.
Others measure the effects. IPHA, the industry body, reports a median of 213 days from EU approval to the first Irish site being ready to take patients, the slowest in the EU for industry trials. The Irish Cancer Society found that only 2 to 3 per cent of cancer patients take part in trials, against a national target of 6 per cent. Earlier coverage on this site looked at IPHA's wait-time figures and cancer trial participation.
Denmark offers a contrast. Since autumn 2025 its medicines agency and ethics committees have reviewed eligible phase I and phase I/II applications within 14 days, and phase I applications rose by almost 80 per cent in a year, according to Invest in Denmark. Denmark starts 38.2 trials of medicines per million a year, against Ireland's 11.8.
Where does Ireland do well?
The story's reading is that getting trials opened is the weak point, not running them. Of trials with Irish sites that closed from 2016 to 2025, 86.9% completed rather than stopping early, 4th of 11. Results were posted for 80.1% of completed phase 2 to 4 trials, 3rd of 11. Ireland lags on registering trials before the first patient joins (82.6%, 9th of 11) and on records left with an "unknown status" label (10.7%, 8th of 11).
How can readers check these numbers?
The story follows the Living Proof Standard, a set of rules Priya Life Science has published for data stories. Every claim is marked as computed, sourced, said on the record or our reading. A "Run the check" button downloads the 47,265 country records behind the edition and recalculates every published number on the reader's device. It also confirms that the file matches the fingerprint of the archived copy on Zenodo (DOI 10.5281/zenodo.24229455). The code is public on GitHub. What Living Proof is and how it works is explained on its own page.
The analysis has limits. It counts only trials registered on ClinicalTrials.gov, not those registered only in the EU's own system (CTIS). A trial with sites in several countries counts once in each. "Not sponsored by industry" uses the registry's sponsor class, which includes universities abroad. AI tools helped find documents, write and test code and draft text; no number was produced by an AI model.
Frequently asked questions
How many clinical trials does Ireland start each year?
About 116 interventional trials a year with at least one Irish site, on average from 2021 to 2025, according to ClinicalTrials.gov. That is 21.3 per million people.
Which countries is Ireland compared with?
Austria, Belgium, Czechia, Denmark, Finland, the Netherlands, Norway, Portugal, Sweden and Switzerland. Denmark, Finland and Norway are each within about a million people of Ireland's size.
Does this mean Irish trials are run badly?
No. Ireland ranks 4th of 11 for trials completed rather than stopped early and 3rd for posting results. The gap is in how many trials start.
What would change the finding?
The story names three things: Ireland's 2026 rate reaching the median in the January 2027 edition; evidence that trials registered only in the EU system are much more common for Ireland; or sponsors showing Irish trials missing from the registry. Any change will be logged in the story.
Did the Department of Health respond?
The Department of Health, the Health Research Board and the HRB National Clinical Trials Office were sent the findings on 5 November 2026 and asked to reply by 11 November. None had replied by publication. Any reply will be added to the story in full, with its date.
Outlook
The next edition of the index, due in January 2027, will give a checked figure for 2026, the first full year after the oversight group reported. Until then, the story's live section counts new Irish trial registrations from the public registry on request. The question it sets out to answer is simple: is the gap closing? Priya Life Science will report the answer either way.
Sources
- Priya Life Science, Living Proof No. 1: Ireland is missing about 73 clinical trials a year, and comes last of 11 countries for trials of medicines, 15 November 2026; data archived at doi.org/10.5281/zenodo.24229455
- Priya Life Science, Ireland Clinical Trials Performance Index, edition 2026 Q4, 28 October 2026; doi.org/10.5281/zenodo.23725680
- US National Library of Medicine, ClinicalTrials.gov API v2, records pulled 27 October 2026
- Eurostat, population on 1 January (table tps00001), 2025 figures
- Department of Health, National Clinical Trials Oversight Group final report, November 2025
- Department of Health, Appointment of a chair of the new Clinical Trials Advisory Council, July 2026
- Health Manager, New group to develop recommendations to increase number of clinical trials in Ireland, August 2024
- IPU Review, IPHA pushes for reforms in clinical trials, June 2026
- Irish Cancer Society, Report reveals Ireland initiates one third of the interventional clinical trials compared to Denmark, September 2024
- Invest in Denmark, Denmark's fast-track model drives surge in phase I clinical trial applications, September 2026
Cover image: AI-generated illustration (Google Gemini). It is not a photograph of a real place or person, and it shows no real data.